Skip to main content

ROLE OF MUSCLE STRESS KINASES IN OBESITY RELATED DISEASES

PID2019-104399RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

  • Lima, Nátalia da Silva
  • Fernández Fondevila, Marcos
  • Novoa Deaño, Eva María
  • Buqué, Xabier
  • Mercado Gómez, María
  • Gallet, Sarah
  • González Rellán, María Jesús
  • Fernández Paz, Uxía
  • Loyens, Anne
  • García Vence, María
  • Chantada Vázquez, María del Pilar
  • Bravo López, Susana Belén
  • Marañón Barnusell, Patricia
  • Senra Viñas, Ana
  • Escudero Pérez, Adriana
  • Leiva Arjona, Magdalena
  • Guallar Artal, Diana
  • Fidalgo Pérez, Miguel Ángel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio Buzo, Guadalupe
  • Varela Rey, Marta María
  • Cardoso Delgado, Teresa
  • Montero Vallejo, Rocío
  • Ampuero, Javier
  • López Pérez, Miguel A.
  • Diéguez González, Carlos
  • Herrero, Laura
  • Serra Cucurull, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
  • Iruzubieta, Paula
  • Crespo García, Javier
  • Martínez Chantar, María Luz
  • García Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Aspichueta, Patricia
  • Nogueiras Pozo, Rubén
Non-alcoholic fatty liver disease (NAFLD) is a major health threat in both developed and developing countries and is a precursor of the more advanced liver diseases, including non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Currently, understanding the multiple and complex molecular pathways implicated in NAFLD onset and progression is a major priority. The transcription factor p63, which belongs to a family comprising p53, p63, and p73,1 is one of many factors that contributes to the development of liver steatosis. The role of p63 as a tumor suppressor and in cell maintenance and renewal is well studied, but we have recently reported that it is also relevant in the control of lipid metabolism.2 p63 encodes multiple isoforms that can be grouped into 2 categories; isoforms with an acidic transactivation domain (TA) and those without this domain (domain negative). The TAp63α isoform is elevated in the liver of animal models of NAFLD as well as in liver biopsies from obese patients with NAFLD. Furthermore, downregulation of p63α in the liver attenuates liver steatosis in diet-induced obese (DIO) mice, while the activation of TAp63α increases hepatic fat content, mediated by the activation of IKKβ and endoplasmic reticulum stress.2 A specialized form of autophagy that degrades lipid droplets, termed “lipophagy”, is a major pathway of lipid mobilization in hepatocytes. Lipophagy is elevated in hepatoma cells upon exposure to free fatty acids,3 and reduces the fatty acid load in mouse hepatocytes.4 Its impairment has been associated with the development of fatty liver and insulin resistance3,5; in contrast, the autophagic flux is increased during the activation of hepatic stellate cells.6 In the present study, we used an unbiased proteomics approach to gain insight into novel proteins modulating lipid metabolism in the liver of mice with genetic knockdown or overexpression of TAp63α. We found that autophagy-related gene 3 (ATG3) was upregulated by TAp63α activation and downregulated after p63α inhibition. ATG3 is elevated in several animal models of NAFLD and in the liver of patients with NAFLD. Genetic overexpression of ATG3 increased the lipid load in hepatocytes, while its repression alleviated TAp63α- and diet-induced steatosis. ATG3 exerted its role in lipid metabolism by regulating SIRT1 and mitochondrial function. Collectively, these findings identify ATG3 as a novel factor implicated in the development of steatosis
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

p38γ and p38δ regulate postnatal cardiac metabolism through glycogen synthase 1

  • Santamans, Ayelén M.
  • Montalvo-Romeral, Valle
  • Mora, Alfonso
  • Lopez, Juan Antonio
  • Gonzalez-Romero, Francisco
  • Jimenez-Blasco, Daniel
  • Rodríguez, Elena
  • Pintor-Chocano, Aránzazu
  • Casanueva-Benítez, Cristina
  • Acín-Pérez, Rebeca
  • Leiva-Vega, Luis
  • Duran, Joan
  • Guinovart, Joan J.
  • Jiménez-Borreguero, Jesús
  • Enríquez, José Antonio
  • Villlalba-Orero, María
  • Bolaños, Juan P.
  • Aspichueta, Patricia
  • Vázquez, Jesús
  • González-Terán, Bárbara
  • Sabio, Guadalupe
During the first weeks of postnatal heart development, cardiomyocytes undergo a major adaptive metabolic shift from glycolytic energy production to fatty acid oxidation. This metabolic change is contemporaneous to the up-regulation and activation of the p38γ and p38δ stress-activated protein kinases in the heart. We demonstrate that p38γ/δ contribute to the early postnatal cardiac metabolic switch through inhibitory phosphorylation of glycogen synthase 1 (GYS1) and glycogen metabolism inactivation. Premature induction of p38γ/δ activation in cardiomyocytes of newborn mice results in an early GYS1 phosphorylation and inhibition of cardiac glycogen production, triggering an early metabolic shift that induces a deficit in cardiomyocyte fuel supply, leading to whole-body metabolic deregulation and maladaptive cardiac pathogenesis. Notably, the adverse effects of forced premature cardiac p38γ/δ activation in neonate mice are prevented by maternal diet supplementation of fatty acids during pregnancy and lactation. These results suggest that diet interventions have a potential for treating human cardiac genetic diseases that affect heart metabolism., G.S. is a YIP EMBO member. B.G.T. was a fellow of the FPI Severo Ochoa CNIC program (SVP-2013-067639) and currently is funded by the AHA-CHF (AHA award number: 818798). V.M.R. is a FPI fellow (BES-2014-069332) and A.M.S. is a fellow of the FPI Severo Ochoa CNIC program (BES-2016-077635). This work was funded by the following grants: to G.S.: funding from the EFSD/Lilly European Diabetes Research Programme Dr Sabio, from Spanish Ministry of Science, Innovation and Universities (MINECO-FEDER SAF2016-79126-R and PID2019-104399RB-I00), Comunidad de Madrid (IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/BMD-3733) and Fundación Jesús Serra; to P.A.: Ayudas para apoyar grupos de investigación del sistema Universitario Vasco (IT971-16 to P.A.), MCIU/AEI/FEDER, funding from Spanish Ministry of Science, Innovation and Universities (RTI2018-095134-B-100); Excellence Network Grant from MICIU/AEI (SAF2016-81975-REDT and 2018-PN188) to PA and GS; to J.V.: funding from Spanish Ministry of Science, Innovation and Universities (PGC2018-097019-B-I00), the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria grant PRB3 (PT17/0019/0003- ISCIII-SGEFI / ERDF, ProteoRed), and “la Caixa” Banking Foundation (project code HR17-00247); to J.P.B.: funding from Spanish Ministry of Science, Innovation and Universities (PID2019-105699RB-I00, RED2018‐102576‐T) and Escalera de Excelencia (CLU-2017-03); to J.A.E.: funding from Spanish Ministry of Science, Innovation and Universities MINECO (RED2018-102576-T, RTI2018-099357-B-I00), CIBERFES (CB16/10/00282), and HFSP (RGP0016/2018). RAP (XPC/BBV1602 and MIN/RYC1102). The CNIC is supported by the Ministry of Science, Innovation and Universities and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

p38 MAPK priming boosts VSMC proliferation and arteriogenesis by promoting PGC1α‑dependent mitochondrial dynamics

  • Sahún-Español, Álvaro
  • Clemente, Cristina
  • Jiménez-Loygorri, Juan Ignacio
  • Sierra-Filardi, Elena
  • Herrera-Melle, Leticia
  • Gómez-Durán, Aurora
  • Sabio, Guadalupe
  • Monsalve, María
  • Boya, Patricia
  • Arroyo, Alicia G.
17 p.-6 fig., Vascular smooth muscle cell (VSMC) proliferation is essential for arteriogenesis to restore blood flow after artery occlusion, but the mechanisms underlying this response remain unclear. Based on our previous findings showing increased VSMC proliferation in the neonatal aorta of mice lacking the protease MT4-MMP, we aimed at discovering new players in this process. We demonstrate that MT4-MMP absence boosted VSMC proliferation in vitro in response to PDGF-BB in a cell-autonomous manner through enhanced p38 MAPK activity. Increased phospho-p38 in basal MT4-MMP-null VSMCs augmented the rate of mitochondrial degradation by promoting mitochondrial morphological changes through the co-activator PGC1α as demonstrated in PGC1α−/− VSMCs. We tested the in vivo implications of this pathway in a novel conditional mouse line for selective MT4-MMP deletion in VSMCs and in mice pre-treated with the p38 MAPK activator anisomycin. Priming of p38 MAPK activity in vivo by the absence of the protease MT4-MMP or by anisomycin treatment led to enhanced arteriogenesis and improved flow recovery after femoral artery occlusion. These findings may open new therapeutic opportunities for peripheral vascular diseases., Funding was provided by the Spanish Ministerio de Ciencia e Innovación (AEI/FEDER, UE), SAF2017-83229-R and PID2020-112981RB-I00 (AGA), PID2020-114709RA-I00 (AGD), PID2019-104399RB-I00 (GS), RTI2018-093864-B-I00 (MM), PGC2018-098557-B-I00 (PB), PRE2019-088222 (JIJL) and the Spanish Ministerio de Educación, Cultura y Deporte, FPU15-05802 (LHM). ASE was supported by fellowships from Obra Social La Caixa, Ford-Apadrina La Ciencia and La Residencia de Estudiantes. AGD is an Atracción de Talento M1 Fellow from Comunidad de Madrid (Spain) [2019-T1BMD-14236]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight

  • Ferreira, Vítor
  • Folgueira, Cintia
  • Guillén Gómez, María José
  • Zubiaur, Pablo
  • Navares-Gómez, Marcos
  • Sarsenbayeva, Assel
  • López-Larrubia, Pilar
  • Eriksson, Jan W.
  • Pereira, Maria J.
  • Abad-Santos, Francisco
  • Sabio, Guadalupe
  • Rada, Patricia
  • Valverde, Ángela M.
[Background]: Second-generation antipsychotics (SGAs) are a mainstay therapy for schizophrenia. SGA-treated patients present higher risk for weight gain, dyslipidemia and hyperglycemia. Herein, we evaluated the effects of olanzapine (OLA), widely prescribed SGA, in mice focusing on changes in body weight and energy balance. We further explored OLA effects in protein tyrosine phosphatase-1B deficient (PTP1B-KO) mice, a preclinical model of leptin hypersensitivity protected against obesity., [Methods]: Wild-type (WT) and PTP1B-KO mice were fed an OLA-supplemented diet (5 mg/kg/day, 7 months) or treated with OLA via intraperitoneal (i.p.) injection or by oral gavage (10 mg/kg/day, 8 weeks). Readouts of the crosstalk between hypothalamus and brown or subcutaneous white adipose tissue (BAT and iWAT, respectively) were assessed. The effects of intrahypothalamic administration of OLA with adenoviruses expressing constitutive active AMPKα1 in mice were also analyzed., [Results]: Both WT and PTP1B-KO mice receiving OLA-supplemented diet presented hyperphagia, but weight gain was enhanced only in WT mice. Unexpectedly, all mice receiving OLA via i.p. lost weight without changes in food intake, but with increased energy expenditure (EE). In these mice, reduced hypothalamic AMPK phosphorylation concurred with elevations in UCP-1 and temperature in BAT. These effects were also found by intrahypothalamic OLA injection and were abolished by constitutive activation of AMPK in the hypothalamus. Additionally, OLA i.p. treatment was associated with enhanced Tyrosine Hydroxylase (TH)-positive innervation and less sympathetic neuron-associated macrophages in iWAT. Both central and i.p. OLA injections increased UCP-1 and TH in iWAT, an effect also prevented by hypothalamic AMPK activation. By contrast, in mice fed an OLA-supplemented diet, BAT thermogenesis was only enhanced in those lacking PTP1B. Our results shed light for the first time that a threshold of OLA levels reaching the hypothalamus is required to activate the hypothalamus BAT/iWAT axis and, therefore, avoid weight gain., [Conclusion]: Our results have unraveled an unexpected metabolic rewiring controlled by hypothalamic AMPK that avoids weight gain in male mice treated i.p. with OLA by activating BAT thermogenesis and iWAT browning and a potential benefit of PTP1B inhibition against OLA-induced weight gain upon oral treatment., This work was funded by grants PID-2021-122766OB-100 (to AMV) and PID2019-104399RB-I00 (to GS) funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación /10.13039/501100011033 and “ERDF A way of making Europe” by the European Union. We also acknowledge grants H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement 721236, European Commission), S2017/BMD-3684 (Comunidad de Madrid, Spain), Fundación Ramón Areces (Spain) and CIBERdem (ISCIII, Spain) to AMV. JWE was funded by the Swedish Diabetes Foundation and the Novo Nordisk Foundation (NNF20OC0063864). VF was a recipient of a contract from ITN-TREATMENT and is currently a PhD fellow from the Portuguese Foundation for Science and Technology (FCT, Portugal)/ERDF (2020.08388.BD). CF was awarded with Sara Borrell contract (CD19/00078, ISCIII, Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

  • Lima, Natália da Silva
  • Fondevila, Marcos F.
  • Nóvoa, Eva
  • Buqué, Xabier
  • Mercado-Gómez, María
  • Gallet, Sarah
  • González-Rellán, María Jesús
  • Fernández, Uxía
  • Loyens, Anne
  • García-Vence, María
  • Chantada-Vázquez, María del Pilar
  • Bravo, Susana Belén
  • Marañón, Patricia
  • Senra, Ana
  • Escudero, Adriana
  • Leiva, Magdalena
  • Guallar, Diana
  • Fidalgo, Miguel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio, Guadalupe
  • Varela-Rey, Marta
  • Delgado, Teresa C.
  • Montero-Vallejo, Rocío
  • Ampuero, Javier
  • López, Miguel
  • Diéguez, Carlos
  • Herrero, Laura
  • Serra, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
  • Iruzubieta, Paula
  • Crespo, Javier
  • Martínez-Chantar, María Luz
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Aspichueta, Patricia
  • Nogueiras, Rubén
[Background & Aims] Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation process, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes to non-alcoholic fatty liver disease (NAFLD) remains unknown., [Methods] By performing proteomic analysis on livers from mice with genetic manipulation of hepatic p63, a regulator of fatty acid metabolism, we identified ATG3 as a new target downstream of p63. ATG3 was evaluated in liver samples from patients with NAFLD. Further, genetic manipulation of ATG3 was performed in human hepatocyte cell lines, primary hepatocytes and in the livers of mice., [Results] ATG3 expression is induced in the liver of animal models and patients with NAFLD (both steatosis and non-alcoholic steatohepatitis) compared with those without liver disease. Moreover, genetic knockdown of ATG3 in mice and human hepatocytes ameliorates p63- and diet-induced steatosis, while its overexpression increases the lipid load in hepatocytes. The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a (CPT1a), and mitochondrial function. Hepatic knockdown of SIRT1 and CPT1a blunts the effects of ATG3 on mitochondrial activity. Unexpectedly, these effects are independent of an autophagic action., [Conclusions] Collectively, these findings indicate that ATG3 is a novel protein implicated in the development of steatosis., This work has been supported by grants from FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (PA: RTI2018-095134-B-100; DS and LH: SAF2017-83813-C3-1-R; MLMC: RTC2019-007125-1; CD: BFU2017-87721; ML: RTI2018–101840-B-I00; GS; PID2019-104399RB-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; MLMC: SAF2017-87301-R; TCD: RTI2018-096759-A-100), FEDER/Instituto de Salud Carlos III (AGR: PI19/00123), Xunta de Galicia (ML: 2016-PG068; RN: 2015-CP080 and 2016-PG057), Fundación BBVA (RN, GS and MLM), Proyectos Investigación en Salud (MLMC: DTS20/00138), Sistema Universitario Vasco (PA: IT971-16); Fundación Atresmedia (ML and RN), Fundación La Caixa (M.L., R.N. and M.C.), Gilead Sciences International Research Scholars Program in Liver Disease (MVR), Marató TV3 Foundation (DS: 201627), Government of Catalonia (DS: 2017SGR278) and European Foundation for the Study of Diabetes (RN and GS). This research also received funding from the European Community’s H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to RN, VP and MS). Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem). CIBERobn, CIBERehd and CIBERdem are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition

  • Ferreira, Vítor
  • Folgueira, Cintia
  • García-Altares, María
  • Guillén Gómez, María José
  • Ruíz-Rosario, Mónica
  • DiNunzio, Giada
  • García-Martínez, Irma
  • Alén, Rosa
  • Bookmeyer, Christoph
  • Jones, John G.
  • Cigudosa, Juan C.
  • López-Larrubia, Pilar
  • Correig, Xavier
  • Davis, Roger J.
  • Sabio, Guadalupe
  • Rada, Patricia
  • Valverde, Ángela M.
Olanzapine (OLA), a widely used second-generation antipsychotic (SGA), causes weight gain and metabolic alterations when administered orally to patients. Recently, we demonstrated that, contrarily to the oral treatment which induces weight gain, OLA administered via intraperitoneal (i.p.) in male mice resulted in body weight loss. This protection was due to an increase in energy expenditure (EE) through a mechanism involving the modulation of hypothalamic AMPK activation by higher OLA levels reaching this brain region compared to those of the oral treatment. Since clinical studies have shown hepatic steatosis upon chronic treatment with OLA, herein we further investigated the role of the hypothalamus-liver interactome upon OLA administration in wild-type (WT) and protein tyrosine phosphatase 1B knockout (PTP1B–KO) mice, a preclinical model protected against metabolic syndrome. WT and PTP1B–KO male mice were fed an OLA-supplemented diet or treated via i.p. Mechanistically, we found that OLA i.p. treatment induces mild oxidative stress and inflammation in the hypothalamus in a JNK1-independent and dependent manner, respectively, without features of cell dead. Hypothalamic JNK activation up-regulated lipogenic gene expression in the liver though the vagus nerve. This effect concurred with an unexpected metabolic rewiring in the liver in which ATP depletion resulted in increased AMPK/ACC phosphorylation. This starvation-like signature prevented steatosis. By contrast, intrahepatic lipid accumulation was observed in WT mice treated orally with OLA; this effect being absent in PTP1B–KO mice. We also demonstrated an additional benefit of PTP1B inhibition against hypothalamic JNK activation, oxidative stress and inflammation induced by chronic OLA i.p. treatment, thereby preventing hepatic lipogenesis. The protection conferred by PTP1B deficiency against hepatic steatosis in the oral OLA treatment or against oxidative stress and neuroinflammation in the i.p. treatment strongly suggests that targeting PTP1B might be also a therapeutic strategy to prevent metabolic comorbidities in patients under OLA treatment in a personalized manner., This work was funded by grants PID-2021-122766OB-100 (to AMV), PID2019-104399RB-I00 (to GS) and RTI2018-096061-B-I00 (to XCB) funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union. We also acknowledge grants H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement 721236, European Commission), P2022/BMD-7227 (Comunidad de Madrid, Spain), Fundación Ramón Areces (Spain) and CIBERdem (ISCIII, Spain) to AMV. VF was a recipient of a contract from ITN-TREATMENT and is currently a PhD fellow from the Portuguese Foundation for Science and Technology (2020.08388.BD, FCT, Portugal)/ERDF. CF was awarded with Sara Borrell contract (CD19/00078, ISCIII, Spain). MGA has a postdoctoral contract 2018 BP 00188 funded by AGAUR (Spain), while CB is recipient of a postdoctoral contract from HORIZON-MSCA-2021-PF-01 MASS2 (Proposal number 101067953)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MCJ: A mitochondrial target for cardiac intervention in pulmonary hypertension

  • Santamans, Ayelén M.
  • Cicuéndez, Beatriz
  • Mora, Alfonso
  • Villalba-Orero, María
  • Rajlic, Sanela
  • Crespo, María
  • Vo, Paula
  • Jerome, Madison
  • Macías, Álvaro
  • López, Juan Antonio
  • Leiva, Magdalena
  • Rocha, Susana F.
  • León, Marta
  • Rodríguez, Elena
  • Leiva-Vega, Luis
  • Pintor-Chocano, Aránzazu
  • García-Lunar, Inés
  • García-Álvarez, Ana
  • Hernansanz-Agustín, Pablo
  • Peinado, Víctor
  • Barberà, Joan Albert
  • Ibáñez, Borja
  • Vázquez, Jesús
  • Spinelli, Jessica B.
  • Daiber, Andreas
  • Oliver, Eduardo
  • Sabio, Guadalupe
17 p.-6 fig.-2 tab., Pulmonary hypertension (PH) can affect both pulmonary arterial tree and cardiac function, often leading to right heart failure and death. Despite the urgency, the lack of understanding has limited the development of effective cardiac therapeutic strategies. Our research reveals that MCJ modulates mitochondrial response to chronic hypoxia. MCJ levels elevate under hypoxic conditions, as in lungs of patients affected by COPD, mice exposed to hypoxia, and myocardium from pigs subjected to right ventricular (RV) overload. The absence of MCJ preserves RV function, safeguarding against both cardiac and lung remodeling induced by chronic hypoxia. Cardiac-specific silencing is enough to protect against cardiac dysfunction despite the adverse pulmonary remodeling. Mechanistically, the absence of MCJ triggers a protective preconditioning state mediated by the ROS/mTOR/HIF-1α axis. As a result, it preserves RV systolic function following hypoxia exposure. These discoveries provide a potential avenue to alleviate chronic hypoxia-induced PH, highlighting MCJ as a promising target against this condition., This study was financially supported by the following: Interacciones celulares y sistémicas entre el cáncer y la señalización metabólica, exp: RED2022-134397-T (G.S.); Proyectos I+D+i 2019 - Proyecto MINECO-PID2019-104399RB-I00 financiado por MCIN/AEI/10.13039/501100011033 (G.S.); Proyectos de I+D de Generación de Conocimiento 2018 funded by Ministerio de Economía y Competitividad (PGC2018-097019-B-I00) (G.S.); PreMed-Exp: PMP21/00057 (G.S.); Fundación Jesús Serra (G.S.); EFSD/Lilly European Diabetes Research Programme (G.S.); BBVA Foundation Leonardo Grants program for Researchers and Cultural Creators (Investigadores-BBVA-2017) (G.S.); Fundación AECC PROYE19047SABI (G.S.); Comunidad de Madrid IMMUNOTHERCAN-CM S2010/BMD-2326 (G.S.); FPI Severo Ochoa CNIC program (BES-2016-077635) (A.M.S.); JDC-2020 Incorporación (IJC2020-042679-I) (P.H.-A.); Fondo Europeo de Desarrollo Regional (FEDER) Instituto de Salud Carlos III-Fondo de Investigación Sanitaria PI17/00995 (A.G.-Á.); Fondo Europeo de Desarrollo Regional (FEDER) Instituto de Salud Carlos III-Fondo de Investigación Sanitaria (PI20/00742) (A.G.-Á.); Intensificación AES2019 (AGA); Fundación “La Caixa”: Macromoleculopathies (LCF/PR/HR19/52160013) of the call HEALTH RESEARCH 2018 (Á.Ma.); Programa de Atracción de Talento (2017-T1/BMD-5185) funded by Comunidad de Madrid (E.O.); Ramón y Cajal grant (RYC2020-028884-I) funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future” (E.O.); Juan de la Cierva Incorporación Grant (IJCI-2016-27698) (M.V.O.); Worcester Foundation for Biomedical Research (J.B.S.); Boehringer Ingelheim Foundation (collaborative research group “Novel and neglected cardiovascular risk factors: molecular mechanisms and therapeutics”) (A.D.); Foundation Heart of Mainz (A.D.); DZHK (German Center for Cardiovascular Research), Partner Site Rhine-Main, Mainz, Germany (A.D.); Ministerio de Ciencia e Innovación (PGC2018-097019-B-I00, PID2021-122348NB-I00, PLEC2022-009235, and PLEC2022-009298) (J.V.); Fundación “La Caixa” (HR17-00247 and HR22-00253) (J.V.); Carlos III Institute of Health-Fondo de Investigación Sanitaria grant PRB3 (PT17/0019/0003- ISCIII-SGEFI/ERDF, ProteoRed) (J.V.); and Comunidad de Madrid (IMMUNO-VAR, P2022/BMD-7333) (J.V.). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Estrogens prevent the hypothalamus-periphery crosstalk induced by olanzapine intraperitoneal treatment in female mice: Effects on brown/beige adipose tissues and liver

  • Ferreira, Vítor
  • Folgueira, Cintia
  • Montes-San Lorenzo, Ángela
  • Rodríguez-López, Andrea
  • Gonzalez-Iglesias, Eva
  • Zubiaur, Pablo
  • Abad-Santos, Francisco
  • Sabio, Guadalupe
  • Rada, Patricia
  • Valverde, Ángela M.
Olanzapine (OLA) is a highly obesogenic second-generation antipsychotic (SGA). Recently we demonstrated that, contrarily to OLA oral treatment, intraperitoneal (i.p.) administration resulted in weight loss and absence of hepatic steatosis in wild-type (WT) and protein tyrosine phosphatase 1B (PTP1B)-deficient (KO) male mice. This protection relied on two central-peripheral axes connecting hypothalamic AMPK with brown/inguinal white adipose tissue (BAT/iWAT) uncoupling protein-1 (UCP-1) and hypothalamic JNK with hepatic fatty acid synthase (FAS). Herein, we addressed OLA i.p. treatment effects in WT and PTP1B-KO female mice. Contrarily to our previous results in WT females receiving OLA orally, the i.p. treatment did not induce weight gain or hyperphagia. Molecularly, in females OLA failed to diminish hypothalamic phospho-AMPK or elevate BAT UCP-1 and energy expenditure (EE) despite the preservation of iWAT browning. Conversely, OLA i.p. treatment in ovariectomized mice reduced hypothalamic phospho-AMPK, increased BAT/iWAT UCP-1 and EE, and induced weight loss as occurred in males. Pretreatment of hypothalamic neurons with 17β-estradiol (E2) abolished OLA effects on AMPK. Moreover, neither hypothalamic JNK activation nor hepatic FAS upregulation were found in WT and PTP1B-KO females receiving OLA via i.p. Importantly, this axis was reestablished upon ovariectomy. In this line, E2 prevented OLA-induced phospho-JNK in hypothalamic neurons. These results support the role of estrogens in sex-related dimorphism in OLA treatment. This study evidenced the benefit of OLA i.p. administration in preventing its obesogenic effects in female mice that could offer clinical value., This work was funded by grants PID2021-122766OB-I00 (to AMV) and PID2019-104399RB-I00 (to GS) funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union (Spain). We also acknowledge grants H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement 721236, European Commission) (to AMV and FA-S), and P2022/BMD-7227 (Comunidad de Madrid, Spain), and CIBERdem (ISCIII, Spain) (to AMV). VF was a recipient of a contract from ITN-TREATMENT and a PhD fellowship from the Portuguese Foundation for Science and Technology (2020.08388.BD, FCT, Portugal)/ERDF. CF was awarded with Sara Borrell contract (CD19/00078, ISCIII, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Absence of MCJ/DnaJC15 promotes brown adipose tissue thermogenesis

  • Cicuéndez, Beatriz
  • Mora, Alfonso
  • López, Juan Antonio
  • Curtabbi, Andrea
  • Pérez-García, Javier
  • Porteiro, Begoña
  • Jimenez-Blasco, Daniel
  • Latorre-Muro, Pedro
  • Vo, Paula
  • Jerome, Madison
  • Gómez-Santos, Beatriz
  • Romero-Becerra, Rafael
  • Leiva, Magdalena
  • Rodríguez, Elena
  • León, Marta
  • Leiva-Vega, Luis
  • Gómez-Lado, Noemi
  • Torres, Jorge L.
  • Hernández-Cosido, Lourdes
  • Aguiar, Pablo
  • Marcos, Miguel
  • Jastroch, Martin
  • Daiber, Andreas
  • Aspichueta, Patricia
  • Bolaños, Juan P.
  • Spinelli, Jessica B.
  • Puigserver, Pere
  • Enriquez, José Antonio
  • Vázquez, Jesús
  • Folgueira, Cintia
  • Sabio, Guadalupe
Obesity poses a global health challenge, demanding a deeper understanding of adipose tissue (AT) and its mitochondria. This study describes the role of the mitochondrial protein Methylation-controlled J protein (MCJ/DnaJC15) in orchestrating brown adipose tissue (BAT) thermogenesis. Here we show how MCJ expression decreases during obesity, as evident in human and mouse adipose tissue samples. MCJKO mice, even without UCP1, a fundamental thermogenic protein, exhibit elevated BAT thermogenesis. Electron microscopy unveils changes in mitochondrial morphology resembling BAT activation. Proteomic analysis confirms these findings and suggests involvement of the eIF2α mediated stress response. The pivotal role of eIF2α is scrutinized by in vivo CRISPR deletion of eIF2α in MCJKO mice, abrogating thermogenesis. These findings uncover the importance of MCJ as a regulator of BAT thermogenesis, presenting it as a promising target for obesity therapy., We thank Electron Microscopy Facility (Centro Nacional de Biotecnología, CSIC) for preparing samples (Epon embedding), obtaining the ultrathin sections and TEM visualization. The project that gave rise to these results received the support of a fellowship from” la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/DR21/11880010 to B.C. C.F was funded with Sara Borrell (CD19/ 00078), NNF23SA0083952-EASO/Novo Nordisk New Investigator Award in Basic Sciences 2023, EFSD/Lilly Young Investigator Award 2022, Society for Endocrinology/Early Career Grant 2022, FSEEN/ Jóvenes endocrinólogos 2022, EFSD/Novo Nordisk Rising Star 2024, IBSA Foundation Fellowship Endocrinology 2023. This work has been supported by the following projects: PMP21/00057 funded by the Instituto de Salud Carlos III (ISCIII) - European Union (FEDER/FSE) “Una manera de hacer Europa”/ “El FSE invierte en tu futuro”/ Next Generation EU and cofunded by the European Union / Plan de Recuperación, Transformación y Resiliencia (PRTR); PID2022-138525OB-I00 de la Agencia Estatal de Investigación 10.13039/501100011033, financiado por MICIU/AEI/10.13039/501100011033 fondos FEDER and EU, PDC2021-121147-I00 and PID2019-104399RB-I00 funded by MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/Plan de Recuperación Transformación y Resiliencia -PRTR; Grant RED2022-134397-T funded by MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union NextGenerationEU/PRTR”; Fundación Jesús Serra; EFSD/Lilly Dr Sabio; 2017 Leonardo Grant BBVA Foundation (Investigadores-BBVA-2017); Comunidad de Madrid IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/BMD-373; Fundación AECC PROYE19047SABI. PreMed-Exp: PMP21/00057, PMP21/00113 Infraestructura de Medicina de Precisión asociada a la Ciencia y Tecnología IMPACT-2021, Instituto de Salud Carlos III (GS, JLT). The project leading to these results has received funding from the” la Caixa” Foundation under the project code “HR24-00581” (G.S). G.S is a Miembro Numerario of the RACVE. J.P-G was supported by the fellowship from” la Caixa” Foundation (ID 100010434), the fellowship code is LCF/BQ/DR24/12080018. A.C was supported by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement n. 713,673 and by Becas de doctorado INPhINIT “la Caixa” 2018. PLM acknowledges NIH NIDDK grant K99DK133502. M.M is supported by Instituto de Salud Carlos III (ISCIII) and the European Union project PI20/00743. P.A is supported by MCIU/AEI/FEDER, UE (PID2021-124425OB-I00) and Basque Government, Department of Education (IT1476-22) and PMP21/00080 de Medicina de Precisión asociada a la Ciencia y Tecnología IMPACT-2021, Instituto de Salud Carlos III. J.P.B is funded by MICIU/AEI (PID2022-138813OB-I00), la Caixa Foundation (grant agreement LCF/PR/HR23/52430016), Instituto de Salud Carlos III (CB16/10/00282) and the European Union’s Horizon Europe research and innovation program under the MSCA Doctoral Networks 2021 (101072759; FuEl ThEbRaiN In healtThY aging and age-related diseases, ETERNITY), AEI grants PID2019-105699RB-I00, PID2022-138813OB-I00 and PDC2021-121013-I00; HORIZON-MSCA-2021-DN-01grant 101072759; and La Caixa Research Health grant HR23-00793. PP acknowledges NIH grant R01DK136640. JAE was supported by competitive grants: PID2021-127988OB-I00 funded by MCIN/AEI/10.13039/501100011033/ FEDER, UE; Human Frontier Science Program (grant RGP0016/2018), Leducq Transatlantic Networks (17CVD04) and CIBERFES [CB16/10/00282], Centro de Investigación Biomédica. Instituto de Salud Carlos III.The CNIO and CNIC are supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation) and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Resident macrophage-dependent immune cell scaffolds drive anti-bacterial defense in the peritoneal cavity

  • Vega-Pérez, Adrián
  • Villarrubia, Laura H.
  • Godio, Cristina
  • Gutiérrez-González, Alejandra
  • Feo-Lucas, Lidia
  • Ferriz, Margarita
  • Martínez-Puente, Natalia
  • Alcaín, Julieta
  • Mora, Alfonso
  • Sabio, Guadalupe
  • López-Bravo, María
  • Ardavín, Carlos
Peritoneal immune cells reside unanchored within the peritoneal fluid in homeostasis. Here, we examined the mechanisms that control bacterial infection in the peritoneum using a mouse model of abdominal sepsis following intraperitoneal Escherichia coli infection. Whole-mount immunofluorescence and confocal microscopy of the peritoneal wall and omentum revealed that large peritoneal macrophages (LPMs) rapidly cleared bacteria and adhered to the mesothelium, forming multilayered cellular aggregates composed by sequentially recruited LPMs, B1 cells, neutrophils, and monocyte-derived cells (moCs). The formation of resident macrophage aggregates (resMφ-aggregates) required LPMs and thrombin-dependent fibrin polymerization. E. coli infection triggered LPM pyroptosis and release of inflammatory mediators. Resolution of these potentially inflammatory aggregates required LPM-mediated recruitment of moCs, which were essential for fibrinolysis-mediated resMφ-aggregate disaggregation and the prevention of peritoneal overt inflammation. Thus, resMφ-aggregates provide a physical scaffold that enables the efficient control of peritoneal infection, with implications for antimicrobial immunity in other body cavities, such as the pleural cavity or brain ventricles., This work was supported by grants SAF2015-69905, PGC2018-101899-B-100, and S2017/BMD3731 to C.A. and grant PID2019-104399RB-100 to G.S. The CNIC is supported by the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and the Pro CNIC Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

JNK1 in SF1 neurons regulates the central action of thyroid hormones on hepatic lipid metabolism

  • Fernández-González, Iara
  • Freire-Agulleiro, Oscar
  • Ferreira, Vitor
  • Silveira-Loureiro, María
  • Rial-Pensado, Eva
  • Garrido-Gil, Pablo
  • Martínez, Gloria
  • Rada, Patricia
  • Labandeira-Garcia, Jose Luis
  • Mittag, Jens
  • González-García, Ismael
  • Diéguez, Carlos
  • Nogueiras, Rubén
  • Valverde, Ángela M.
  • Davis, Roger J.
  • Sabio, Guadalupe
  • Barca-Mayo, Olga
  • López, Miguel
[Objective] Hypothalamic energy sensors, such as AMP-activated protein kinase (AMPK), and stress sensors, such as c-Jun N-terminal kinase 1 (JNK1, also known as MAPK8) modulate whole body energy balance. While the role of AMPK in steroidogenic factor 1 (SF1) neurons of the VMH has been investigated, the relevance of JNK1 in this neuronal population has not been addressed. Here, we investigated the involvement of JNK1 SF1 on energy homeostasis., [Methods] We generated mice bearing conditional JNK1 disruption through Mapk8 gene deletion in SF1 neurons (Sf1Cre/Jnk1fl/fl). Complete metabolic phenotyping, fasting/refeeding and cold challenges, as well as the central response to triiodothyronine (T3) on brown adipose tissue (BAT) thermogenesis and hepatic lipid metabolism were carried out., [Results] Sf1Cre/Jnk1fl/fl mice displayed decreased body weight, improved glucose tolerance, and reduced hepatic lipid levels. However, Sf1Cre/Jnk1fl/fl did not properly defend their temperature upon cold exposure. While central administration of T3 elicited feeding independent weight loss in both wildtype (Jnk1fl/fl) and SF1Cre/Jnk1fl/fl mice, it did not promote hepatic lipid accretion in null animals., [Conclusions] Our data demonstrated for the first time that JNK1 in SF1 neurons is necessary for the regulation of hepatic lipid metabolism, cold adaptation and central T3 actions., The research leading to these results has received funding from the Xunta de Galicia (IG-G: ED431F 2024/14; IG-G and RN ED431C 2024/10; RN: 2016-PG057; OB-M: ED431F 2020/009 and ED431C 2023/28); Ministerio de Ciencia e Innovación co-funded by the FEDER Program of EU (IG-G: PID2022-141115NA-I00; CD: PID2020-116628 GB-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; AM-V; PID2021-122766OB-100; GS: PID2019-104399RB-I00; PMP21/00057; PDC2021-121147-I00 IMPACT-202; OB-M: PID2019-109556RB-I00; PID2022-138436OB-I00; ML: PID2021-128145NB-I00 and PDC2022-133958-I00); European Research Council (RN: ERC Synergy Grant-2019-WATCH- 810331); “la Caixa” Foundation (ID 100010434), (ML: LCF/PR/HR19/52160022 and LCF/PR/HR20/52400013); Fundación AECC (GS: PROYE19047SABI; ML: PRYGN234908LOPE). IG-G and OB-M are supported by Ramón y Cajal Awards (IG-G: RYC2021-031225-I; OB-M: RYC2018-026293-I) from the Ministerio de Ciencia e Innovación of Spain. OF-A was supported by a fellowship from Xunta de Galicia (ED481A-2019/026). CiMUS was supported by the Xunta de Galicia (2020–2023, ED431G/05). CIBER de Fisiopatología de la Obesidad y Nutrición, CIBER de Diabetes y Enfermedades Metabólicas Asociadas and CIBER de Enfermedades Neurodegenerativas are initiatives of ISCIII., Peer reviewed
Docta Complutense
Publication Artículo científico (JournalArticle)

MCJ: A mitochondrial target for cardiac intervention in pulmonary hypertension

  • Santamans, Ayelén M.
  • Cicuéndez, Beatriz
  • Mora, Alfonso
  • Rajlic, Sanela
  • Crespo, María
  • Vo, Paula
  • Jerome, Madison
  • Macías, Álvaro
  • López, Juan Antonio
  • Rocha, Susana F.
  • León, Marta
  • Rodríguez, Elena
  • Leiva, Luis
  • Pintor Chocano, Aránzazu
  • García Lunar, Inés
  • García-Álvarez, Ana
  • Hernansanz-Agustín, Pablo
  • Peinado, Víctor I.
  • Barberá, Joan Albert
  • Ibañez, Borja
  • Vázquez, Jesús
  • Spinelli, Jessica B.
  • Daiber, Andreas
  • Oliver, Eduardo
  • Sabio, Guadalupe
  • Villalba Orero, María
  • Leiva Arjona, María Magdalena
Pulmonary hypertension (PH) can affect both pulmonary arterial tree and cardiac function, often leading to right heart failure and death. Despite the urgency, the lack of understanding has limited the development of effective cardiac therapeutic strategies. Our research reveals that MCJ modulates mitochondrial response to chronic hypoxia. MCJ levels elevate under hypoxic conditions, as in lungs of patients affected by COPD, mice exposed to hypoxia, and myocardium from pigs subjected to right ventricular (RV) overload. The absence of MCJ preserves RV function, safeguarding against both cardiac and lung remodeling induced by chronic hypoxia. Cardiac-specific silencing is enough to protect against cardiac dysfunction despite the adverse pulmonary remodeling. Mechanistically, the absence of MCJ triggers a protective preconditioning state mediated by the ROS/mTOR/HIF-1α axis. As a result, it preserves RV systolic function following hypoxia exposure. These discoveries provide a potential avenue to alleviate chronic hypoxia-induced PH, highlighting MCJ as a promising target against this condition.